Will L'Oréal's Kering Beauté Acquisition Crush Estée Lauder and Coty in US Prestige Beauty?
Global beauty giant L'Oréal has finalized its acquisition of Kering Beauté, the luxury beauty division of Kering Group, under a strategic alliance between the two French powerhouses. This deal hands L'Oréal control of high-end brands including Bottega Veneta beauty, Balenciaga fragrances, and existing hits like Gucci and Saint Laurent, bolstering its prestige portfolio at a time when US rivals Estée Lauder (EL) and Coty (COTY) are bleeding market share.
Bearish near-term for EL and COTY: With L'Oréal now commanding ~20% more luxury beauty firepower in key US channels, these peers face accelerated erosion in fragrances and skincare—segments where they've already posted double-digit declines.
L'Oréal's Power Play in a Weakening US Beauty Landscape
The acquisition closes a chapter on Kering's beauty ambitions, redirecting focus to fashion while supercharging L'Oréal's luxury stable. Kering Beauté generated €500M+ in annual sales pre-deal, with strong growth in prestige fragrances—a category growing 8-10% globally despite US slowdowns. L'Oréal, already the world's #1 beauty company with €45B revenue, gains instant scale in ultra-premium where margins often exceed 70%.
For US-listed peers, timing couldn't be worse. Both EL and COTY reported FY2025 revenue drops amid inventory gluts, China weakness, and promotional wars. EL's sales fell 8% to $14.29B, with net income swinging to a $1.13B loss. COTY fared marginally better at $5.89B revenue (down 4%), but posted a $368M net loss. Free cash flow held up—EL at $670M, COTY $278M—but stock prices tell the real pain story.
| Metric (TTM/FY2025) | Estée Lauder (EL) | Coty (COTY) | L'Oréal Context (Est.) |
|---|---|---|---|
| Market Cap | $25.1B | $1.76B | €250B+ (post-deal) |
| Revenue Growth | -3.3% | -4.6% | +5-7% organic |
| Gross Margin | 74.4% | 62.4% | ~72% |
| EBIT Margin | 7.3% | 4.09% | 15-18% |
| P/S Ratio | 1.71 | 0.30 | ~4.0 |
| Price Return 1M | -20.8% | -13.7% | +5% (est. ADR equiv.) |
| Price Return 3M | -15.7% | -32.2% | Stable |
EL trades at a premium P/S despite collapsing EPS (-$3.15 diluted FY2025 vs. +$1.08 prior), reflecting hopes for its "Beauty Reimagined" turnaround. COTY's dirt-cheap valuation signals deeper distress, with shares hovering near $2 after a 32% 3M plunge.
Estée Lauder's Prestige Squeeze: Travel Retail Wounds Reopen
EL, with its icons like La Mer and Clinique, derives ~40% of sales from Asia-Pacific prestige—now a L'Oréal stronghold post-deal. Earnings calls highlight "persistent challenges" in Travel Retail (down 28% FY2025) and China share gains by rivals. Management's Profit Recovery and Growth Plan (PRGP) slashed 2,600 jobs and touted 4% Q1 FY2026 organic growth, but guidance tempers enthusiasm: flat-to-3% full-year sales, EPS $2.25-$2.50.
Kering Beauté's US footprint—via Sephora and Nordstrom—directly overlaps EL's channels. Balenciaga's edgy fragrances target Gen Z, eroding M·A·C and Too Faced. EL's 74% gross margins offer cushion, but EBIT at 7.3% lags L'Oréal's efficiency. Recent price action: EL up 2% intraday post-deal news? No—broader 1M drop of 21% underscores sector rot.
Vulnerable spot: EL's FY2025 current ratio (~1.3) strains under $5.4B liabilities, limiting M&A defense. Watch Q1 FY2026 earnings for China traction; further misses could push P/E (N/A on losses) toward COTY's despair.
Coty's Fragrance Fortress Under Siege
COTY leans on licensed fragrances (Burberry, Chloé) for 70%+ revenue, but FY2025 saw Prestige slowdowns from retailer destocking. CEO Sue Nabi flagged U.S. execution woes and Gucci license exit, pivoting to blockbusters like BOSS Beyond Bottled. Yet, EBIT margin scraped 4.09%, with FY2026 guidance eyeing H2 recovery amid tariffs.
L'Oréal inheriting Gucci/St. Laurent amps direct rivalry—COTY's core. Recent daily prices show COTY sliding from $2.69 (Feb) to $2.00 (late March), volume spiking on down days. At 0.3x P/S, it's a value trap unless Prestige rebounds. Skin care push (e.g., CoverGirl) helps, but luxury fragrances remain Achilles' heel.
Numbers don't lie: COTY's FY2025 revenue miss vs. prior $6.12B, FCF dip to $278M. Earnings stress H2 growth via innovation, but L'Oréal's scale (~10x COTY's capex power) dwarfs this.
Investment Takeaway: Fade US Beauty, Accumulate on Panic
Bearish on EL and COTY through 2026: L'Oréal's acquisition cements its US dominance, pressuring already-weak peers amid 3-5% sector growth. EL's turnaround merits patience (target $100/share on 10% sales rebound), but COTY risks further dilution below $1.50.
Monitor: EL's Q2 FY2026 China sales (May call), COTY's fragrance pipeline (tariff offsets), and L'Oréal's integration updates. Next catalyst: Beauty sector M&A wave—could EL sell assets? Or does COTY license defensively?